Assessment of patient performance of the HandiHaler® compared with the metered dose inhaler four weeks after instruction  by Dahl, R et al.
Assessment of patient performance of the
HandiHalers compared with the metered dose
inhaler four weeks after instruction
R. Dahla,*, V. Backerb, B. Ollgaardc, F. Gerkend, S. Kestene
aDepartment of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
bBispebjerg Hospital, University Hospital of Copenhagen, Denmark
cBoehringer Ingelheim, Denmark
dBoehringer Ingelheim, Germany
eBoehringer Ingelheim, USA
Summary The HandiHalers is a novel breath-actuated dry powder system designed
for the delivery of tiotropium 18 mg daily in the treatment of COPD. We compared
patient ability to use the HandiHalers or metered dose inhaler (MDI) device correctly
4 weeks after receiving brief instructions and device demonstration. A single-blind
study was conducted in COPD patients in two centers in Denmark. All patients
(n ¼ 151) received one placebo capsule via the HandiHalers daily and ipratropium
(20 mg) two actuations via the MDI q.i.d. Mean FEV1 for all patients was 1.25þ 0.54
(46% predicted). Twelve instructions establishing proper device use were
evaluated for the MDI and Handihaler. Error scores were analyzed by number of
patients with less, equal or more errors when using HandiHalers compared to
MDI in the total efficacy population (n ¼ 139) and according to those who had not
previously used an MDI for at least 12 months (MDI beginners) (n ¼ 74) and those
who had used an MDI (MDI experienced) (n ¼ 65). Four weeks after device instruction,
a higher proportion of patients in the total population (Po0:01) had fewer errors
with the HandiHalers (35.3%) compared to the MDI (15.1%). The number of
errors was equal in 50% of patients. Similar findings were observed in the
subgroup of patients who were MDI beginners (42% vs. 11%, Po0:01) with non-
significant trends in favor of the HandiHalers in those patients who were MDI
experienced (29.7% vs. 18.9%, P ¼ 0:096). Similar results in favor of HandiHalers
were noted across different age and sex strata. The proportion of patients correctly
using the device on the first of three attempts was 59.7% and 54.7% for the
HandiHalers and MDI, respectively (P ¼ 0:399). In summary, use of the HandiHalers
can be easily taught with fewer errors compared to the MDI. Furthermore, patient
performance using the HandiHalers was superior to that with an MDI despite prior MDI
experience and more frequent usage.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
Inhaled bronchodilators have been a mainstay for
drug delivery in chronic obstructive pulmonary
disease (COPD) for many years.1 Several devices
have been developed to administer inhaled
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pharmacotherapy. There are currently three main
categories of inhaled medication delivery devices.
These include: (1) pressurized metered dose
inhaler (MDI), (2) dry powder inhalation systems
(DPI) and (3) liquid nebulization systems. The MDI
and DPI systems are the most common prescribed
and used delivery devices while the nebulizers are
generally reserved for use in the hospital setting.
The HandiHalers is a dry powder inhaler system
developed for the delivery of tiotropium (SPIRIVAs)
to COPD patients.2–5 Operation of the HandiHalers
is based on the evacuation of powder medication
from a pierced capsule that is achieved by an
inspiratory maneuver by the patient. Studies using
the Andersen Cascade Impactor have shown that
20 l/min is an effective inspiratory flow rate to
cause evacuation of powder from the capsule
containing the medication.2 Additional studies in
COPD patients with low FEV1 (16–65% predicted)
have confirmed that the HandiHalers can be used
effectively.2 Long-term multi-center studies with
tiotropium have confirmed that an effective dose
resulting in bronchodilation and improved sympto-
matic control can be delivered with the HandiHa-
lers dry powder inhalation system.3–5 Given that
the most common option used for delivery of
inhaled medication is the MDI, a trial was
conducted to determine whether use of the
HandiHalers was associated with less
performance errors compared to the MDI and to
assess the ability of COPD patients to learn how to
use the HandiHalers.
Methods
Study design
This was a 4-week, single-blind trial in COPD
patients to compare the HandiHalers to a pressur-
ized MDI with regards to self-administration tech-
nique and the retention of the learned ability to
correctly self-administer medication through each
device. The patients were instructed, trained, and
assessed on use of HandiHaler and MDI. Patients
self-administered placebo capsules (lactose) once
daily with the HandiHalers and ipratropium bro-
mide via the MDI two actuations q.i.d. The patients
but not the investigators were blinded to the
treatment.
Patients
All patients were required to have a diagnosis of
COPD according to American Thoracic Society
Criteria and have documented airflow limitation
with an FEV1 p80% of predicted normal and FEV1
p70% of FVC.6,7 Spirometry conducted up to 6
months prior to the first visit was accepted.
Patients were to be at least 40 years of age and
have had a history of smoking of more than 10 pack-
years. All patients were required to have been
using an inhaled bronchodilator at least once daily.
Patients were excluded if, in the opinion of the
investigator, they had any acute or chronic illness
that could interfere with the conduct or completion
of the trial, had previously used the HandiHalers or
discontinued use of regularly prescribed MDI within
the last 12 months. Patients who had a recent
(within 6 weeks prior to Visit 1) respiratory illness
or had participated in a pulmonary rehabilitation
program in the 6 weeks prior to Visit 1 were also
excluded. The protocol was approved by the
local scientific ethics committee in Aarhus and
Copenhagen, and written informed consent
was obtained before any study procedure was
undertaken.
There were two populations of 80 patients
planned each serving as stratification groups. The
first population consisted of those patients who
were using an MDI at the time of study enrolment
(MDI experienced). The second population (MDI
beginners) consisted of those patients who had not
used an MDI in the preceding 12 months. Patients
were recruited from two centers in Denmark. Each
center was expected to randomize 80 patients.
Patients were recruited from out patient clinics at
the two hospitals and through advertising in local
newspapers.
Study protocol
The trial consisted of two visits separated by 4
weeks. At Visit 1, patients were instructed and
trained in correct use of both the HandiHalers and
the MDI. Thereafter, all patients were asked to
demonstrate that they were able to follow the
instructions by a 12-step checklist assessment for
each device (Table 1). Placebo MDI and placebo
capsules were used at Visits 1 and 2 when
demonstrating and observing the patient’s admin-
istration technique of both devices. Only patients
who were not able to demonstrate use of the
devices without errors after the third attempt were
included in the trial by the investigator. At Visit 1,
prescribed inhaled anticholinergics, regularly
scheduled short-acting b-agonists and combination
(anticholinergic and b-agonists) products were
discontinued. The patients took the last dose of
these medications on the morning of Visit 1.
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Patients who were eligible for the trial
were provided with one blinded MDI containing
ipratropium bromide, to be taken at a dose of two
puffs four times daily, starting in the morning after
Visit 1. Patients were also provided with a
HandiHalers device and blinded placebo capsules
to be taken at a dose of one capsule, once daily,
starting in the morning after Visit 1. The patients
were provided with an open-label salbutamol MDI
labeled as rescue medication. The patients were
informed that they would receive a bronchodilator
but were not informed which device contained
active drug. The patients were sent home with the
HandiHalers device, placebo capsules, a blinded
ipratropium MDI and a labeled salbutamol MDI for 4
weeks. At Visit 2, which occurred after 4 weeks,
the patients took the last dose of study medication
on the morning of Visit 2 before meeting at the out-
patient clinic. At Visit 2 investigators repeated the
assessment of both devices in randomized sequence
(Table 2).
Data analysis
The differences in error rates were tested by means
of a two-sided Wilcoxon signed rank test at level of
significance of 0.05, using the individual differ-
ences in the number of errors when using the two
devices. In addition, the error rates were also
analyzed by means of a linear model including
factors for device, sequence, patient within se-
quence, period, center and population. Main
effects and possible interactions were explored.
The number of errors made on all scoring attempts
at Visit 1 were compared between the devices using
the same method as that for the primary endpoint.
The number of scoring attempts at Visit 1 were
evaluated by frequency tables and the McNemar
test (post hoc analysis) and compared between the
devices.
Results
A total of 152 patients were randomized. One
hundred and fifty-one patients were treated, 81 in
the group of MDI beginners and 70 in the group with
MDI experience. Sixteen patients (10.6% out of 151
randomized and treated patients) discontinued the
study prematurely (11 MDI beginners and five with
MDI experience), and 135 patients completed the
study (70 MDI beginners and 65 with MDI experi-
ence). However, data from Visit 2, available on four
discontinued patients (all were MDI beginners),
were included in the analysis. No differences were
demonstrated between the two centers. Center 1
randomized and treated 72 evaluable patients and
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Table 1 The 12-step checklist for assessment of HandiHalers and MDI usea.
HandiHalers Metered dose inhaler
1 Open the dust cap and the mouthpiece
(white part) of the inhaler
Remove the cap
2 Remove one capsule from the blister pack
and put the capsule in the chamber
Shake the inhaler
3 Close the mouthpiece (click heard) Breathe out through the mouth
4 Hold the HandiHalers with the mouthpiece
upwards
Place the mouthpiece in the mouth, and
close lips around it
5 Press the blue button and release it Hold the inhaler upright
6 Breathe out fully (without the HandiHalers) Begin breathing, then actuate the canister
once
7 Raise the HandiHalers to the mouth and
close lips around the mouthpiece
Continue to breathe in deeply and slowly
through the mouth
8 Slow and deep breath Hold breath for 5–10 s
9 Hold breath for at least 5 s Remove the inhaler from the mouth and
breathe out
10 Remove the HandiHalers out of the mouth
and breathe out slowly
Wait at least 30 s
11 Repeat steps 6–10 once more Shake the inhaler again and repeat steps 3–9
12 Open the mouthpiece again. Hold the inhaler
so that the capsule chamber is pointing
downwards and tip out the used capsule.
Close the mouthpiece and dust cap again
Replace the mouthpiece cap
aA score of 1 was given for each step. The affirmative score was only given if the step was completely correct.
1128 R. Dahl et al.
center 2 randomized and treated 79 evaluable
patients.
Patient demographics
A total of 93 men (61.6%) participated in the trial.
The mean age was 67þ 8 years with a mean FEV1 of
1.25þ 0.54 l (46þ 16% predicted). Nearly all pa-
tients (147/151) were receiving pulmonary medica-
tion at baseline.
Performance scores
Prior to instructions and demonstration regarding
their use of the MDI, MDI experienced patients were
rated according to the 12-step performance check-
list at Visit 1. Fifty-four patients out of 70 (77.1%)
of the population with MDI experience were unable
to use the MDI device without error (Fig. 1).
At Visit 1, patients needed to demonstrate
correct use of both devices after instruction and
demonstration of the use of both devices to remain
in the study after randomization. A maximum of
three attempts was allowed. In the total efficacy
population, 59.7% (HandiHalers) and 54.7% (MDI)
(P ¼ 0:399) of patients recorded proper use on the
first attempt and all patients demonstrated correct
use within three attempts (Fig. 2). In the group of
MDI beginners (74 patients of the efficacy popula-
tion) there were more patients who succeeded with
their first demonstration of HandiHalers use
(58.1%) vs. MDI use (40.5%) (P ¼ 0:037), and more
patients needed two or three attempts for success-
ful use of MDI than for HandiHalers (Fig. 2). As
would be expected, the reverse was found for the
group of MDI experienced patients (65 patients of
the efficacy population). There were more patients
successful with their first demonstration in MDI use
(70.8%) vs. HandiHalers use (61.5%) and more
patients needed two or three attempts for success-
ful use of HandiHalers than for MDI.
The group of MDI beginners demonstrated more
errors with use of the MDI than with the Handi-
Halers. Thirty-one patients (41.9%) made more
errors using MDI than using HandiHalers and 21
patients (28.4%) made more errors using HandiHa-
lers than using MDI. These observed differences
between the use of the MDI and the HandiHalers
among beginners were without statistical signifi-
cance. The mean for the difference of error rates
was 0.27 (HandiHalers–MDI) and was statistically
significant different from zero (Po0:05). The group
of MDI experienced patients demonstrated more
errors with the HandiHalers than with the MDI. The
mean for the difference of error rates was þ 0.17
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Table 2 Patient characteristics at screening.
Total patients (N ¼ 151) MDI-beginner (N ¼ 81) MDI-experienced (N ¼ 70)
Male (%) 62 62 61
Age (years)a 67.1 (7.9) 66.2 (8.3) 68.0 (7.4)
Duration of COPD (years)a 10.4 (7.6) 9.6 (7.1) 11.3 (8.1)
Smoking history (pack-years)a 36.4 (16.3) 33.6 (15.1) 39.6 (17.1)
Current smokers (%) 55.0 55.6 54.3
Baseline medications (% population)
Any pulmonary medication 97 98 97
Inhaled salbutamol 38 20 59
Inhaled salmeterol 40 42 39
Inhaled anticholinergic 33 26 40
Inhaled steroid 45 49 40
aMean (SD).
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Figure 1 Percent of MDI experienced patients who
performed all steps for MDI use without errors and with at
least 1 error at Visit 1.
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(HandiHalers-MDI) but was not statistically signifi-
cantly different from zero.
After 4 weeks use at Visit 2, the patient
performance of device use was rated (Table 3).
More patients had at least one error with the MDI
compared with the HandiHalers (56.8% out of 139
patients of the efficacy population with errors in
MDI use and 46.0% with errors in HandiHalers use).
This result was also observed in the subgroups
defined by MDI experience. Twenty-one patients
(15.1%) made more errors using the HandiHalers
than using MDI and 49 patients (35.3%) made more
errors using the MDI than using HandiHalers. This
observed difference between results for devices
was statistically significant (Po0:01). In addition,
the observed difference between results for de-
vices was statistically significant (Po0:01) when
patients were stratified according to MDI experi-
ence. The difference in the subgroup of MDI
beginners was numerically but not statistically
different in favor of the HandiHalers (P ¼ 0:096).
Due to inconsistent interpretation of one specific
patient instruction for the devices across centers,
the primary analysis was repeated ignoring step 10
of the HandiHalers performance hecklist (‘Remove
the HandiHalers out of the mouth and breath out
slowly’) and step 9 of the MDI performance check-
list (‘Remove the inhaler from the mouth and
breath out’). The judgement of what constituted
‘breathing out slowly’ was different between
centers. As this does not impact delivery of
medication, the analysis excluding this step was
relevant. The results of the primary analysis were
confirmed. Furthermore, patients made statisti-
cally significantly fewer errors using HandiHalers
than using MDI within all analyzed subgroups using
both, Wilcoxon signed rank test (Po0:0133) and
ANOVA (Table 4).
Age and gender analysis
The performance results following 4 weeks of use
(Visit 2) were categorized according to the age and
gender of the patients. For both devices, the
incidence of errors increased with age; however,
in all age subgroups, the percentages of patients
correctly performing every step of HandiHalers use
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Figure 2 Percent of patients who performed all steps for
HandiHaler and MDI use without errors by attempt in
the total population and according to MDI experience at
Visit 1.
Table 3 Number of patients with errors for performance checklists at Visit 2.
HandiHalers MDI device
Total MDI-beginner MDI-exp Total MDI-beginner MDI-exp
Patients, n (%) 139 (100) 74 (100) 65 (100) 139 (100) 74 (100) 65 (100)
Patients with X1 error, n (%) 64 (46.0) 32 (43.2) 32 (49.2) 79 (56.8) 39 (52.7) 40 (61.5)
Errors per patient, mean (SD) 0.7 (0.9) 0.7(0.9) 0.7 (0.9) 1.0 (1.1) 0.9 (1.0) 1.1 (1.2)
Table 4 Number of patients with errors for performance checklists at Visit 2 excluding step 10 for the HandiHaler and
step 9 for the MDI.
HandiHalers MDI device
Total MDI-beginner MDI-exp Total MDI-beginner MDI-exp
Patients, n (%) 139 (100) 74 (100) 65 (100) 139 (100) 74 (100) 65 (100)
Patients with X1 error, n (%) 33 (23.7) 15 (20.3) 18 (27.7) 61 (43.9) 30 (40.5) 31 (47.7)
Errors per patient, mean (SD) 0.3 (0.7) 0.3 (0.7) 0.3 (0.6) 0.7 (0.9) 0.6 (0.9) 0.8 (1.0)
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were higher than for MDI use (Fig. 3). The incidence
of errors occurring while demonstrating the use of
either device at Visit 2 was higher in female
patients than in male patients. For both sexes, a
greater percentage of patients correctly demon-
strated use of the HandiHalers compared with
correct use of the MDI (Fig. 4).
Discussion
Inhaled therapies are the preferred treatment
modalities for COPD.1 Assuring the proper training
of health care professionals, correct patient use of
inhaled delivery systems and improved compliance
continues to be a challenge in meeting treatment
goals for COPD. To complicate this matter, the ideal
delivery device needs to be designed with con-
siderations for providing consistent delivery of a set
amount of medication of the optimal particle size,
to the lung. In this report we have compared the
self-administration performance using either the
HandiHalers or MDI over the course of a 4-week
clinical trial in COPD patients.
The HandiHalers is a breath activated dry
powder system for delivery of tiotropium 18 mg,
once daily. As the MDI remains the most common
mode of delivering inhaled medication world-wide,
a comparison of the ability to learn how to use the
HandiHalers and MDI and retention of such learning
was performed.8 Initial instruction was followed by
an uninterrupted 4-week period of use. To replicate
the actual frequency of use over the course of a
day, patients were instructed to use the HandiHa-
lers once daily and use the MDI four times daily. At
the end of 4 weeks, the HandiHalers appeared
easier to learn, by virtue of fewer mistakes
associated with use, compared to the MDI, and this
difference was statistically significant. After in-
struction and demonstration, MDI inexperienced
patients needed fewer attempts to demonstrate
appropriate HandiHalers use than did patients
using the MDI. After 4 weeks, MDI beginners as well
as MDI experienced patients made fewer errors
using the HandiHalers than MDI. In addition, a
lower proportion of patients had one or more errors
using the HandiHalers vs. the MDI, although this
did not reach statistical significance. Patients using
the HandiHalers delivery device made fewer errors
compared with those who used the MDI and were
better able to retain instructions for proper use.
Bronchodilator therapy for the treatment of
COPD may be administered by oral, sub-cutaneous,
intravenous or inhaled route for drugs with topical
activity. Inhalation provides the therapeutic ad-
vantage of local delivery to the lung, thereby,
reducing the required dose for bronchodilation and
minimizing the potential for adverse effects by
systemic bioavailability. Inhalation of bronchodila-
tors also allows for a more rapid onset of action
compared with systemic delivery.9 DPI systems have
been widely used and have gained acceptance over
the last decade and have several advantages over
pressurized aerosol systems. DPIs do not contain
propellants and are therefore, in compliance with
the mandate to decrease the use of freon-CFC
propellants according to the Montreal Protocol.10
Furthermore, DPIs are breath-actuated and elim-
inate the need for coordination of inspiration and
activation of the pressurized aerosol MDI.11 In
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addition, MDI devices often require a spacer unit to
help minimize uncoordinated inspiration and drug
activation, while DPI systems do not. Lastly, DPI
systems either have built in actuation counters or
utilize a single unit dose format which eliminates
continued use of an empty container.12
However, there are areas where MDIs can be
considered to compare favorably to DPIs. Several
currently available DPI systems use single unit
dosing and require reloading of the medication
into a chamber with each administration; whereas
MDIs which contain up to 200 actuations in a single
unit. If required for rescue treatment for relief of
acute respiratory symptoms, a re-loading system
for a DPI could be a problem. A drawback with the
DPI system, not observed with the MDI, is that these
non-pressurized devices cannot currently be used in
intubated patients. In general, these issues with
DPI systems arise from inconveniences and are not
detrimental to the use or efficacy of the device
under normal conditions.
The standard pressurized MDI has been repeat-
edly associated with performance problems in
patients.13 Errors in performance may result in an
inadequate or ineffective dose of medication
delivered to the lung.11 As the deficiencies with
the MDI have been recognized, alternative pressur-
ized MDIs and DPI systems have been developed, to
improve performance and delivery characteristics
for inhalation devices. However, as with all devices,
patient instruction is required and there is still a
need to follow several steps for optimal use.
Therefore, a formal evaluation of ability to use a
device is required to adequately assess the device’s
suitability for the intended patient population.
There have been reports evaluating the perfor-
mance and adequacy of drug delivery from novel
dry powder inhalation systems.14–18 In one 4-week
study, the attributes and patient acceptability of
the Accuhaler was compared with the pressurized
MDI. In this 4-week study, patients preferred the
Accuhaler over the MDI on the basis of ease of
use.16 Another study of 318 patients with obstruc-
tive lung disease demonstrated that as many as 70%
of patients made errors on inhalation technique
with a dry powder device after receiving instruc-
tions.14 However, correct usage among health care
professionals was the highest for the pressurized
MDI compared with either the Turbuhaler (budeso-
nide) or Diskus (salmeterol).18 Similarly, it was
found that pharmacists were able to correctly
demonstrate use for the MDI compared with the
Turbuhaler.15 These findings support the concept
that proper professional training is essential to
increase the likelihood of proper patient technique
independent of whether the device is an MDI or one
of the different powder inhalers. Lastly, a compar-
ison of the MDI and dry powder delivery of
ipratropium was evaluated in COPD patients. The
results of that study demonstrated equal efficacy
for post drug improvements in FEV1 for both
devices.17 In summary, the data from these trials
suggest the need for clinical trials in order to
evaluate patient acceptance, proper training and
use of new inhalation devices for the delivery of
bronchodilators.
The results of this study demonstrated that fewer
mistakes were made with the HandiHalers device
compared with the MDI. There were, however,
limitations to this study. Device comparison was
single blind, which in not atypical for these types of
investigations. The trial was conducted over 4
weeks, which limited the exposure time of the
patients to the devices. In addition, one of the
devices had active medication (MDI) while the
other (HandiHalers) held placebo; however, the
bias here would favor the MDI. In the current study
it is important to note that there was a problem
with interpretation of one of the instruction steps
for both HandiHalers and MDI use. In order to
address this issue, we analyzed the data from the
trial with and without the inclusion of this step
(step 10 for HandiHalers and step 9 for MDI). The
result was the same regardless of whether or not
this step was included in the analysis. Finally, there
were different frequencies of daily administration
(q.i.d. vs. once daily), although, again, this should
favor MDI performance. While patient ability to
correctly use an inhalation device varies, there is
clearly a need for improvement in the current
design of the pressurized MDI systems to reduce the
incidence of errors with medication delivery. For
many years, MDIs have been the standard for
inhalation therapy; however, in recent years the
evidence suggests that patients can experience
difficulty using all devices, which results in poor
delivery of pharmacotherapy to the lung. The
results of this study demonstrated that the ability
of COPD patients to use the HandiHalers dry
powder system was more easily learned with
improved administration performance compared
with the pressurized aerosol MDI system.
References
1. Global initiative for chronic obstructive lung disease (GOLD),
Global strategy for the diagnosis, management, and pre-
vention of chronic obstructive pulmonary disease (executive
summary). National Institutes of Health, 2001.
2. Chodosh S, Flanders JS, Kesten S, Serby CW, et al. Effective
delivery of particles with the HandiHaler dry powder
ARTICLE IN PRESS
1132 R. Dahl et al.
inhalation system over a range of chronic obstructive
pulmonary disease severity. J Aerosol Med 2001;14:309–15.
3. Casaburi R, Mahler DA, Jones PA, et al. A long-term
evaluation of once-daily inhaled tiotropium in chronic
obstructive pulmonary disease. Eur Respir J 2002;19:217–24.
4. Vincken W, van Noord JA, Greefhorst APM, et al. Improved
health outcomes in patients with COPD during one year
treatment with tiotropium. Eur Respir J 2002;19:209–16.
5. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month,
placebo-controlled study comparing lung function and
health status changes in COPD patients treated with
tiotropium or salmeterol. Chest 2002;122:47–55.
6. American Thoracic Society. Standardization of spirometry:
1994 update. Am J Respir Crit Care Med 1995;152:1107–36.
7. Quanjer PH, Tammeling GJ, Cotes JE, et al. , Lung volumes
and forced ventilatory flows. Report Working Party Standar-
dization of Lung Function Tests, European Community for
Steel and Coal. Official Statement of the European Respira-
tory Society. Eur Respir J Suppl 1993;16:5–40.
8. Fink JB. Metered-dose inhalers, dry powder inhalers, and
transitions. Respir Care 2000;45:623–35.
9. Grimwood K, Fergusson DM, Dawson KP. Combination of
salbutamol inhalational powder and tablets in asthma. Arch
Dis Child 1983;58:283–5.
10. D’Souza S. The Montreal Protocol and essential use exemp-
tions. J Aerosol Med 1995;8(Suppl 1):S13–7.
11. McFadden Jr. ER. Improper patient techniques with metered
dose inhalers: clinical consequences and solutions to misuse.
J Allergy Clin Immunol 1995;96:278–83.
12. Cain WT, Oppenheimer JJ. The misconception of using
floating patterns as an accurate means of measuring the
contents of metered-dose inhaler devices. Ann Allergy
Asthma Immunol 2001;87:417–9.
13. Kesten S, Elias M, Cartier A, Chapman KR. Patient handling
of a multidose dry powder inhalation device for albuterol.
Chest 1994;105:1077–81.
14. van Beerendonk I, Mesters I, Mudde AN, Tan TD. Assessment
of the inhalation technique in outpatients with asthma
or chronic obstructive pulmonary disease using a
metered-dose inhaler or dry powder device. J Asthma
1998;35:273–9.
15. Kesten S, Zive K, Chapman KR. Pharmacist knowledge and
ability to use inhaled medication delivery systems. Chest
1993;104:1737–42.
16. Liam CK, Lim KH, Wong CM. Acceptance of the Accuhaler, a
multi-dose powder inhaler, among asthmatic patients: a
comparison with the pressurized metered-dose inhaler.
Asian Pac J Allergy Immunol 2000;18:135–40.
17. Cuvelier A, Muir JF, Benhamou D, et al. Dry powder
ipratropium bromide is as safe and effective as metered-
dose inhaler formulation: a cumulative dose–response study
in chronic obstructive pulmonary disease patients. Respir
Care 2002;47:159–66.
18. Chopra N, Oprescu N, Fask A, Oppenheimer J. Does
introduction of new ‘‘easy to use’’ inhalational
devices improve medical personnel’s knowledge
of their proper use? Ann Allergy Asthma Immunol
2002;88:395–400.
ARTICLE IN PRESS
Assessment of patient performance of the HandiHaler 1133
